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Safety of Once Daily Enoxaparin for Anticoagulation Bridging in
Patients with HeartMate III Left Ventricular Assisted Device
M. Alom,1 Y. Yaacoub,1 G. Bhattal,1 N. Kabra,1 D. Rawitscher,1 T.
George,2 S. Joseph,3 and A. Afzal.4 1Advanced Heart Failure and
Transplant Cardiology, Baylor University Medical Center/The Heart
Hospital Plano, Plano, TX; 2Cardiothoracic Surgery, Baylor University
Medical Center/The Heart Hospital Plano, Plano, TX; 3Advanced Heart
Failure and Transplant Cardiology, University of Maryland, College Park,
MD; and the 4Advanced Heart Failure and Transplant Cardiology, Baylor
University Medical Center/Texas A&M School of Medicine, Plano, TX.
Purpose: Most centers bridge patients with Left Ventricular Assist Device
(LVAD) patients with heparin drip to avoid thromboembolic complications
based on data from HeartMate II. Because of improved hemocompatibility
of third generation HeartMate III (HM3), Low molecule weight heparin like
enoxaparin has been used to bridge to warfarin when the INR (International
Normalized Ratio) is subtherapeutic. Once daily dosing has been used in
select patients with higher bleeding risk. However, data supporting this
approach is limited. We investigate the safety of using once daily Enoxaparin dosing to bridge subtherapeutic warfarin in patients on HMIII LVAD.
Methods: We conducted a retrospective review of patients who underwent
HMIII LVAD implantation from 2018 to 2020. We identified 22 patients who
received enoxaparin daily bridging after LVAD implantation. We investigated
complications related to enoxaparin use and the necessary data parameters to
determine the safety profile of once daily enoxaparin use. The primary outcome was in-pump thrombosis. Secondary outcomes included ischemic
stroke, embolic phenomenon, acute kidney injury and bleeding events.
Results: 52 patients were screened, 22 patients of which bridged at least
once with enoxaparin. 10 patients received multiple rounds of enoxaparin
bridging over their course of follow up. The average enoxaparin course
was 3-7 days and extended only if INR remains below 1.6. Enoxaparin
was held once the INR reaches 1.8. There were no incidence of pump
thrombosis, ischemic stroke or embolic phenomenon related to enoxaparin
bridging. No significant events were noted in terms of worsening thrombocytopenia, anemia, renal function, bleeding events, or rates of infection.
Conclusion: Once daily enoxaparin dosing as a bridge to subtherapeutic
anticoagulation with warfarin for HM III patients is a safe and effective
method for preventing pump thrombosis while significantly reducing the
need for hospital admissions for heparin bridging.

(1146)
Peri-Operative Warfarin Protocol to Decrease Length of Stay After Left
Ventricular Assist Device Implantation
L. Hencken,1 G. Grafton,2 L. To,1 H. Nemeh,3 and J.
Cowger.2 1Pharmacy, Henry Ford Hospital, Detroit, MI; 2Cardiology,

Henry Ford Hospital, Detroit, MI; and the 3Cardiac Surgery, Henry Ford
Hospital, Detroit, MI.
Purpose: A limitation to left ventricular assist device (LVAD) implantation is cost with fixed reimbursement rates for the LVAD implantation hospitalization regardless of hospital length of stay and costs. Patients must
have a therapeutic INR on warfarin prior to discharge which can take days
and delay discharge. The purpose of this study is to evaluate the impact of
a peri-operative warfarin protocol on decreasing length of stay during
index LVAD implantation.
Methods: This is a retrospective single center study of adult patients
undergoing LVAD implantation between January 1, 2019 and December
31, 2020. Patients who died during the admission were excluded. Patients
in the intervention group (INT) underwent LVAD between January 1December 31, 2020. The peri-operative warfarin protocol included preoperative vitamin K dosing according to INR, initiation of warfarin by
post-operative day (POD) 3, and warfarin titration scheme. The historical
control group (CON) included patients receiving LVADs between January
1-December 31, 2019. Warfarin start date was at the discretion of providers. All patients had a goal INR of 2-3. Endpoints included length of
stay, post-operative warfarin start date, time to therapeutic INR, warfarin
dosing requirements, pre-operative vitamin K dosing and bleeding
complications.
Results: Seventy-seven patients were included; n=41 (53.2%) CON and
n=36 (46.8%) INT. Total hospital length of stay was 35 [26,43] days in the
CON group compared to 27.5 [24,35] days in the INT group (p=0.095).
Warfarin was started earlier in the INT group (POD 5.5 [2.8,7.0]) compared to the CON group (POD 8 [6,14]) (p=0.004). Time to therapeutic
INR remained the same between the two groups with a median of 6 days.
Pre-operative vitamin K decreased from 15 [10,15] mg in the CON group
to 5 [0.0,11.3] mg in the INT group (p=<0.001). There was no increase in
bleeding with the peri-operative warfarin interventions: 8 bleeds in the
CON group and 4 bleeds in the INT group.
Conclusion: Initiating warfarin earlier post-operatively may help decrease
hospital length of stay after LVAD implantation without increasing bleeding events.
(1147)
Impact of Statins on the Incidence of Gastrointestinal Bleeding Events
Among Patients with Continuous Flow Left Ventricular Assist Devices
H. Halawi,1 J.E. Harris,1 D. Putney,1 D.T. Nguyen,2 E.A. Graviss,2 and
M. Kassi.3 1Department of Pharmacy, Houston Methodist Hospital,
Houston, TX; 2Department of Pathology and Genomic Medicine, Houston
Methodist Research Institute, Houston, TX; and the 3Department of
Cardiology, Houston Methodist Hospital, Houston, TX.
Purpose: Patients with continuous flow left ventricular assist devices
(CF-LVADs) are at an increased risk of gastrointestinal bleeding
(GIB) events due to von Willebrand factor degradation, enhanced
angiogenesis and endothelial dysfunction resulting from non-pulsatile
flows of the device. LVAD patients also commonly receive statins for
the primary or secondary prevention of cardiovascular disease. However, the impact of such therapy on the incidence of GIB is controversial. Importantly, literature regarding the impact of statins on GIB in
LVAD patients is lacking.
Methods: This was a single-center, retrospective review of adult patients
that underwent CF-LVAD implantation between May 2016 and January
2020. Patients were categorized based on statin use throughout the study
period. The primary outcome was the composite of arteriovenous malformation (AVM) confirmed GIB and other major GIB events for up to 1year post-LVAD implantation. Secondary outcomes included each of the
components of the primary outcome, non-clinically relevant GIB, time to
GIB, and frequency of GIB. Multivariable Cox regression was utilized to
assess association between confounding variables and major GIB.
Results: Of the 123 patients who met inclusion criteria, 66 (54%) received
statin therapy during the study period. No difference was observed in the
primary outcome of major GIB between the statin and non-statin groups
(21.2% vs. 12.3%, p=0.20). Similarly, AVM confirmed GIB (12.1% vs.
5.3%, p=0.20), other major GIB (9.1% vs. 7.0%, p=0.75), and non-
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